Clinical significance of autoantibodies in autoimmune hepatitis

Journal of Autoimmunity

Volumn 46, Issue , 2013, Pages 17-24

  Liberal, Rodrigo ^a,b   Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b University of Porto   (Portugal)

Author keywords

Anti liver cytosol antibody; Anti liver kidney microsomal antibody; Anti nuclear antibody; Anti smooth muscle antibody; Anti soluble liver antigen; Autoimmune hepatitis

Indexed keywords

ACTIN ANTIBODY; ANTINUCLEAR ANTIBODY; ASIALOGLYCOPROTEIN RECEPTOR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CYTOCHROME P450 1A2 ANTIBODY; CYTOCHROME P450 2D6; DOUBLE STRANDED DNA ANTIBODY; ENZYME ANTIBODY; F ACTIN; IMMUNOSUPPRESSIVE AGENT; LIVER CYTOSOL TYPE 1 ANTIBODY; LIVER KIDNEY MICROSOMAL TYPE 1 ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PANCREAS ANTIGEN ANTIBODY; RECEPTOR ANTIBODY; SMOOTH MUSCLE ACTIN; SMOOTH MUSCLE ANTIBODY; SOLUBLE LIVER ANTIGEN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; AUTOIMMUNE HEPATITIS; CONSENSUS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FULMINANT HEPATIC FAILURE; HELA CELL; HEPATITIS C; HUMAN; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW;

ANTI-LIVER CYTOSOL ANTIBODY; ANTI-LIVER KIDNEY MICROSOMAL ANTIBODY; ANTI-NUCLEAR ANTIBODY; ANTI-SMOOTH MUSCLE ANTIBODY; ANTI-SOLUBLE LIVER ANTIGEN; AUTOIMMUNE HEPATITIS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS, AUTOIMMUNE; HUMANS; MUSCLE, SMOOTH;

EID: 84886287047     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.08.001     Document Type: Review

References (77)

1. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
2. Vergani D., Alvarez F., Bianchi F.B., Cancado E.L., Mackay I.R., Manns M.P., et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. JHepatol 2004, 41:677-683.
3. Gregorio G.V., Portmann B., Karani J., Harrison P., Donaldson P.T., Vergani D., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
4. Liberal R., Longhi M.S., Grant C.R., Mieli-Vergani G., Vergani D. Autoimmune hepatitis after liver transplantation. Clin Gastroenterol Hepatol 2012, 10:346-353.
5. Selmi C., Bowlus C.L., Gershwin M.E., Coppel R.L. Primary biliary cirrhosis. Lancet 2011, 377:1600-1609.
6. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. NEngl J Med 2005, 353:1261-1273.
7. Czaja A.J., Homburger H.A. Autoantibodies in liver disease. Gastroenterology 2001, 120:239-249.
8. Weller T.H., Coons A.H. Fluorescent antibody studies with agents of varicella and herpes zoster propagated invitro. Proc Soc Exp Biol Med 1954, 86:789-794.
9. Vergani D., Longhi M.S., Bogdanos D.P., Ma Y., Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009, 31:421-435.
10. Mackay I.R., Cowling D.C., Taft L.I. Lupoid hepatitis. Lancet 1956, 271:1323-1326.
11. Czaja A.J., Cassani F., Cataleta M., Valentini P., Bianchi F.B. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997, 42:1688-1696.
12. Tan E.M., Feltkamp T.E., Smolen J.S., Butcher B., Dawkins R., Fritzler M.J., et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997, 40:1601-1611.
13. Hilario M.O., Len C.A., Roja S.C., Terreri M.T., Almeida G., Andrade L.E. Frequency of antinuclear antibodies in healthy children and adolescents. Clin Pediatr (Phila) 2004, 43:637-642.
14. Burlingame R.W., Rubin R.L., Rosenberg A.M. Autoantibodies to chromatin components in juvenile rheumatoid arthritis. Arthritis Rheum 1993, 36:836-841.
15. Czaja A.J., Nishioka M., Morshed S.A., Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994, 107:200-207.
16. Strassburg C.P., Alex B., Zindy F., Gerken G., Luttig B., Meyer zum Buschenfelde K.H., et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. JHepatol 1996, 25:859-866.
17. Nishioka M., Morshad S.A., McFarlane I.G. Geographical variation in the frequency and characteristics of autoimmune liver diseases. Autoimmune liver diseases 1998, 413-428. Elsevier, Amsterdam. E.L. Krawitt, R.H. Wiesner, M. Nishioka (Eds.).
18. Gregorio G.V., McFarlane B., Bracken P., Vergani D., Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002, 35:515-519.
19. Strassburg C.P., Manns M.P. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002, 22:339-352.
20. Szostecki C., Krippner H., Penner E., Bautz F.A. Autoimmune sera recognize a 100kD nuclear protein antigen (sp-100). Clin Exp Immunol 1987, 68:108-116.
21. Bandin O., Courvalin J.C., Poupon R., Dubel L., Homberg J.C., Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996, 23:1020-1024.
22. Wesierska-Gadek J., Hohenuer H., Hitchman E., Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996, 110:840-847.
23. Tan E.M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989, 44:93-151.
24. Adams L.A., Lindor K.D., Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004, 99:1316-1320.
25. Bottazzo G.F., Florin-Christensen A., Fairfax A., Swana G., Doniach D., Groeschel-Stewart U. Classification of smooth muscle autoantibodies detected by immunofluorescence. JClin Pathol 1976, 29:403-410.
26. Muratori P., Muratori L., Agostinelli D., Pappas G., Veronesi L., Granito A., et al. Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity 2002, 35:497-500.
27. Gabbiani G., Ryan G.B., Lamelin J.P., Vassalli P., Majno G., Bouvier C.A., et al. Human smooth muscle autoantibody. Its identification as antiactin antibody and a study of its binding to "nonmuscular" cells. Am J Pathol 1973, 72:473-488.
28. Lidman K., Biberfeld G., Fagraeus A., Norberg R., Torstensson R., Utter G., et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976, 24:266-272.
29. Toh B.H. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol 1979, 38:621-628.
30. Kurki P., Linder E., Miettinen A., Alfthan O. Smooth muscle antibodies of actin and "non-actin" specificity. Clin Immunol Immunopathol 1978, 9:443-453.
31. Bogdanos D.P., Mieli-Vergani G., Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009, 29:241-253.
32. Czaja A.J., Cassani F., Cataleta M., Valentini P., Bianchi F.B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996, 24:1068-1073.
33. Granito A., Muratori L., Muratori P., Pappas G., Guidi M., Cassani F., et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. JClin Pathol 2006, 59:280-284.
34. Gregorio G.V., Portmann B., Reid F., Donaldson P.T., Doherty D.G., McCartney M., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997, 25:541-547.
35. Manns M.P., Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006, 43:S132-S144.
36. Rizzetto M., Swana G., Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973, 15:331-344.
37. Mieli-Vergani G., Heller S., Jara P., Vergani D., Chang M.H., Fujisawa T., et al. Autoimmune hepatitis. JPediatr Gastroenterol Nutr 2009, 49:158-164.
38. Lenzi M., Ballardini G., Fusconi M., Cassani F., Selleri L., Volta U., et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 1990, 335:258-259.
39. Bogdanos D.P., Choudhuri K., Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001, 21:225-232.
40. Kerkar N., Choudhuri K., Ma Y., Mahmoud A., Bogdanos D.P., Muratori L., et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. JImmunol 2003, 170:1481-1489.
41. Manns M.P., Griffin K.J., Sullivan K.F., Johnson E.F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. JClin Invest 1991, 88:1370-1378.
42. Mackie F.D., Peakman M., Yun M., Sallie R., Smith H., Davies E.T., et al. Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology 1994, 106:1672-1675.
43. Strassburg C.P., Obermayer-Straub P., Alex B., Durazzo M., Rizzetto M., Tukey R.H., et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996, 111:1576-1586.
44. Philipp T., Durazzo M., Trautwein C., Alex B., Straub P., Lamb J.G., et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994, 344:578-581.
45. Csepregi A., Nemesanszky E., Luettig B., Obermayer-Straub P., Manns M.P. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol 2001, 96:910-911.
46. Bourdi M., Larrey D., Nataf J., Bernuau J., Pessayre D., Iwasaki M., et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. JClin Invest 1990, 85:1967-1973.
47. Simmonds M.J., Gough S.C. Genetic insights into disease mechanisms of autoimmunity. Br Med Bull 2004, 71:93-113.
48. Mathis D., Benoist C. Aire. Annu Rev Immunol 2009, 27:287-312.
49. Lankisch T.O., Strassburg C.P., Debray D., Manns M.P., Jacquemin E. Detection of autoimmune regulator gene mutations in children with type 2 autoimmune hepatitis and extrahepatic immune-mediated diseases. JPediatr 2005, 146:839-842.
50. Lankisch T.O., Mourier O., Sokal E.M., Habes D., Lacaille F., Bridoux-Henno L., et al. AIRE gene analysis in children with autoimmune hepatitis type I or II. JPediatr Gastroenterol Nutr 2009, 48:498-500.
51. Martini E., Abuaf N., Cavalli F., Durand V., Johanet C., Homberg J.C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988, 8:1662-1666.
52. Han S., Tredger M., Gregorio G.V., Mieli-Vergani G., Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995, 21:58-62.
53. Lenzi M., Manotti P., Muratori L., Cataleta M., Ballardini G., Cassani F., et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995, 36:749-754.
54. Muratori L., Cataleta M., Muratori P., Manotti P., Lenzi M., Cassani F., et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. JImmunol Methods 1995, 187:259-264.
55. Lapierre P., Hajoui O., Homberg J.C., Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999, 116:643-649.
56. Muratori L., Cataleta M., Muratori P., Lenzi M., Bianchi F.B. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998, 42:721-726.
57. Wies I., Brunner S., Henninger J., Herkel J., Kanzler S., Meyer zum Buschenfelde K.H., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000, 355:1510-1515.
58. Manns M., Gerken G., Kyriatsoulis A., Staritz M., Meyer zum Buschenfelde K.H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987, 1:292-294.
59. Ma Y., Okamoto M., Thomas M.G., Bogdanos D.P., Lopes A.R., Portmann B., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.
60. Costa M., Rodriguez-Sanchez J.L., Czaja A.J., Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol 2000, 121:364-374.
61. Hagen E.C., Andrassy K., Chernok E., Daha M.R., Gaskin G., Gross W., et al. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. JImmunol Methods 1993, 159:1-16.
62. McFarlane I.G., McFarlane B.M., Major G.N., Tolley P., Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol 1984, 55:347-354.
63. Treichel U., Gerken G., Rossol S., Rotthauwe H.W., Meyer zum Buschenfelde K.H., Poralla T. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. JHepatol 1993, 19:55-63.
64. Treichel U., McFarlane B.M., Seki T., Krawitt E.L., Alessi N., Stickel F., et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994, 107:799-804.
65. Manns M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Vergani G., Vergani D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
66. Johnson P.J., McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
67. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. JHepatol 1999, 31:929-938.
68. Hov J.R., Boberg K.M., Karlsen T.H. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008, 14:3781-3791.
69. Mieli-Vergani G., Vergani D. Autoimmune hepatitis in children: what is different from adult AIH?. Semin Liver Dis 2009, 29:297-306.
70. Abuaf N., Johanet C., Chretien P., Martini E., Soulier E., Laperche S., et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992, 16:892-898.
71. Kerkar N., Hadzic N., Davies E.T., Portmann B., Donaldson P.T., Rela M., et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998, 351:409-413.
72. Dubel L., Farges O., Johanet C., Sebagh M., Bismuth H. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 1998, 65:1072-1075.
73. Salcedo M., Vaquero J., Banares R., Rodriguez-Mahou M., Alvarez E., Vicario J.L., et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002, 35:349-356.
74. Mieli-Vergani G., Vergani D. De novo autoimmune hepatitis after liver transplantation. JHepatol 2004, 40:3-7.
75. Czaja A.J., Morshed S.A., Parveen S., Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997, 26:567-572.
76. Czaja A.J., Pfeifer K.D., Decker R.H., Vallari A.S. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996, 41:1733-1740.
77. Kanzler S., Weidemann C., Gerken G., Lohr H.F., Galle P.R., Meyer zum Buschenfelde K.H., et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. JHepatol 1999, 31:635-640.